[go: up one dir, main page]

CY1115665T1 - Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv - Google Patents

Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv

Info

Publication number
CY1115665T1
CY1115665T1 CY20141100755T CY141100755T CY1115665T1 CY 1115665 T1 CY1115665 T1 CY 1115665T1 CY 20141100755 T CY20141100755 T CY 20141100755T CY 141100755 T CY141100755 T CY 141100755T CY 1115665 T1 CY1115665 T1 CY 1115665T1
Authority
CY
Cyprus
Prior art keywords
forms
inspector
psychological
hiv protection
hiv
Prior art date
Application number
CY20141100755T
Other languages
English (en)
Inventor
Hans Wim Pieter Vermeersch
Daniel Joseph Christiaan Thoné
Luc Donné Marie-Louise Janssens
Piet Tom Bert Paul Wigernick
Original Assignee
Janssen R&D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115665(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R&D Ireland filed Critical Janssen R&D Ireland
Publication of CY1115665T1 publication Critical patent/CY1115665T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Αποκαλύπτονται νέες ψευδοπολυμορφικές μορφές του (3R,3aS,6aR)-εξαϋδροφουρο[2,3-b] φουραν-3-υλ (1S,2R)-3-[[4-αμινοφαινυλ) σουλφονυλ] (ισοβουτυλ) αμινο]-1-βενζυλ-2-υδροξυπροπυλκαρβαμιδικού και διαδικασίες για την παραγωγή τους.
CY20141100755T 2002-05-16 2014-09-17 Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv CY1115665T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02076929 2002-05-16
EP10180831.9A EP2314591B2 (en) 2002-05-16 2003-05-16 Pseudopolymorphic forms of a hiv protease inhibitor

Publications (1)

Publication Number Publication Date
CY1115665T1 true CY1115665T1 (el) 2017-01-25

Family

ID=29724454

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20141100755T CY1115665T1 (el) 2002-05-16 2014-09-17 Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv
CY20141100756T CY1117928T1 (el) 2002-05-16 2014-09-17 Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv
CY20171100896T CY1119311T1 (el) 2002-05-16 2017-08-23 Ψευδο-πολυμορφικες μορφες καταστολεα πρωτεασης hiv

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20141100756T CY1117928T1 (el) 2002-05-16 2014-09-17 Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv
CY20171100896T CY1119311T1 (el) 2002-05-16 2017-08-23 Ψευδο-πολυμορφικες μορφες καταστολεα πρωτεασης hiv

Country Status (25)

Country Link
US (8) US7700645B2 (el)
EP (4) EP3045460B1 (el)
JP (1) JP4864320B2 (el)
KR (2) KR101128370B1 (el)
CN (1) CN100475819C (el)
AP (1) AP2052A (el)
AU (2) AU2003271740B2 (el)
BR (1) BRPI0311176B8 (el)
CA (1) CA2485834C (el)
CY (3) CY1115665T1 (el)
DK (3) DK2314591T4 (el)
EA (1) EA007120B8 (el)
ES (4) ES2498370T5 (el)
HR (1) HRP20041061B1 (el)
HU (1) HUE034389T2 (el)
IL (1) IL165140A0 (el)
LT (1) LT2767539T (el)
MX (1) MXPA04011427A (el)
NO (1) NO331477B1 (el)
NZ (1) NZ536497A (el)
PL (1) PL215151B1 (el)
PT (3) PT2767539T (el)
SI (3) SI2767539T1 (el)
WO (1) WO2003106461A2 (el)
ZA (1) ZA200410154B (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2362404T5 (es) 1998-06-23 2015-11-25 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Ensayo de aptitud y métodos para reducir la resistencia del VIH a terapia
EP3045460B1 (en) 2002-05-16 2019-04-17 Janssen Sciences Ireland Unlimited Company Pseudopolymorphic forms of a hiv protease inhibitor
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
JP4818124B2 (ja) 2003-12-23 2011-11-16 テイボテク・フアーマシユーチカルズ・リミテツド （３Ｒ，３ａＳ，６ａＲ）−ヘキサヒドロフロ〔２，３−ｂ〕フラン−３−イル（１Ｓ，１Ｒ）−３−〔〔（４−アミノフェニル）スルホニル〕（イソブチル）アミノ〕−１−ベンジル−２−ヒドロキシプロピルカルバマートの製造方法
DK1856125T3 (da) 2005-02-25 2009-12-07 Tibotec Pharm Ltd Syntese af proteasehæmmerforstadie
ME01232B (me) * 2006-11-09 2013-06-20 Tibotec Pharm Ltd Etode za dobivanje heksahidrofuro[2,3-b]furan-3-ola
TWI482775B (zh) 2008-09-01 2015-05-01 Tibotec Pharm Ltd 用於製備（３ｒ，３ａｓ，６ａｒ）－六氫呋喃并〔２，３－ｂ〕呋喃－３－基（１ｓ，２ｒ）－３－〔〔（４－胺基苯基）磺醯基〕（異丁基）胺基〕－１－苯甲基－２－羥基丙基胺基甲酸酯之方法
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
CA2750774A1 (en) * 2009-01-29 2010-08-05 Mapi Pharma Hk Limited Polymorphs of darunavir
PL2477992T3 (pl) 2009-09-17 2017-07-31 Mylan Laboratories Limited Proces przygotowania Darunawiru i jego amorficznych postaci
BR112012009956A2 (pt) 2009-10-30 2015-09-29 Lupin Ltd um novo processo para a preparação de darunavir e etanolato darunavir de tamanho de partícula.
EP2513116B1 (en) * 2009-12-16 2015-08-19 Hetero Research Foundation Polymorphs of darunavir
KR20120123077A (ko) * 2010-01-05 2012-11-07 씨아이피엘에이 엘티디. 다루나비르 다형체 및 그의 제조 방법
US8829208B2 (en) 2010-01-28 2014-09-09 Mapi Pharma Ltd. Process for the preparation of darunavir and darunavir intermediates
ES2595235T3 (es) 2010-05-20 2016-12-28 Hetero Research Foundation Sal clorhidrato cristalina de darunavir
WO2012107889A1 (en) 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of amorphous darunavir
CA2838659C (en) 2011-07-07 2020-02-18 Janssen R&D Ireland Darunavir combination formulations
WO2013114382A1 (en) 2011-12-05 2013-08-08 Mylan Laboratories Ltd Crystalline darunavir
US9643976B2 (en) * 2012-01-18 2017-05-09 Aurobindo Pharma Ltd. Solvates of darunavir
CN103509031B (zh) * 2012-06-20 2016-04-27 上海迪赛诺药业有限公司 制备达芦那韦无定形物的方法
WO2014016660A2 (en) 2012-07-24 2014-01-30 Laurus Labs Private Limited A process for preparation of darunavir
KR102186030B1 (ko) 2012-10-29 2020-12-03 시플라 리미티드 항 바이러스성 포스포네이트 유사체 및 이의 제조를 위한 방법
US9346820B2 (en) * 2013-09-11 2016-05-24 Purdue Research Foundation HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
WO2016092525A1 (en) 2014-12-12 2016-06-16 Lupin Limited Darunavir n-propanol solvate and process for preparation thereof
MX381344B (es) 2015-03-19 2025-03-12 Mycovia Pharmaceuticals Inc Compuestos antifungicos y procesos para la fabricacion.
US11045423B2 (en) 2016-08-08 2021-06-29 Hetero Labs Limited Anti-retroviral compositions
BR112019002120A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composição anti-retroviral de várias classes
EP3532478B1 (en) 2016-10-27 2021-05-26 Gilead Sciences, Inc. Crystalline form of darunavir free base
CN108727401A (zh) * 2017-04-20 2018-11-02 盐城迪赛诺制药有限公司 达鲁那韦新晶型及其制备方法和应用
CN109053753A (zh) * 2018-08-05 2018-12-21 浙江大学 一种制备达卢那韦二水合物晶型的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
JPH05230044A (ja) 1992-02-21 1993-09-07 Hoechst Japan Ltd ピレタニドの新規な結晶多形
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
DK0715618T3 (da) * 1993-08-24 1999-08-23 Searle & Co Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser
EP0812320B1 (en) 1995-02-22 2000-07-12 Hoechst Pharmaceuticals & Chemicals K.K. Amorphous piretanide, piretanide polymorphs, process for their preparation and their use
ZA984514B (en) 1997-05-29 1998-11-30 Merck & Co Inc Hiv protease inhibitor
GB9712253D0 (en) 1997-06-13 1997-08-13 Glaxo Group Ltd Antiviral compound
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
ES2362404T5 (es) * 1998-06-23 2015-11-25 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Ensayo de aptitud y métodos para reducir la resistencia del VIH a terapia
WO1999067254A2 (en) * 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
AU1735000A (en) 1998-11-19 2000-06-05 Du Pont Pharmaceuticals Company Crystalline (-)-6- chloro-4- cyclopropylethynyl- 4-trifluoromethyl- 3,4-dihydro-2(1h)-quinazolinone
JP4814427B2 (ja) 1999-02-12 2011-11-16 バーテックス ファーマシューティカルズ インコーポレイテッド アスパルチルプロテアーゼのインヒビター
EP3045460B1 (en) 2002-05-16 2019-04-17 Janssen Sciences Ireland Unlimited Company Pseudopolymorphic forms of a hiv protease inhibitor
KR20120123077A (ko) * 2010-01-05 2012-11-07 씨아이피엘에이 엘티디. 다루나비르 다형체 및 그의 제조 방법

Also Published As

Publication number Publication date
AP2052A (en) 2009-10-05
EP2314591B2 (en) 2021-02-24
ES2728735T3 (es) 2019-10-28
CA2485834A1 (en) 2003-12-24
US20170260196A1 (en) 2017-09-14
WO2003106461A2 (en) 2003-12-24
SI2767539T1 (sl) 2017-10-30
PL374321A1 (en) 2005-10-17
HRP20041061A2 (en) 2006-07-31
ZA200410154B (en) 2005-12-28
US20100204316A1 (en) 2010-08-12
US20180312517A1 (en) 2018-11-01
BRPI0311176B1 (pt) 2019-08-20
ES2503551T5 (es) 2021-10-28
EP2314591A1 (en) 2011-04-27
US10000504B2 (en) 2018-06-19
PT2767539T (pt) 2017-08-28
EP1567529B1 (en) 2014-06-18
US7700645B2 (en) 2010-04-20
SI2314591T2 (sl) 2021-08-31
AU2003271740B2 (en) 2010-05-13
PT1567529E (pt) 2014-09-09
HRP20041061B1 (hr) 2015-02-27
WO2003106461A3 (en) 2004-05-13
US20150336980A1 (en) 2015-11-26
NZ536497A (en) 2006-08-31
EA007120B8 (ru) 2012-03-30
CN100475819C (zh) 2009-04-08
DK2767539T3 (en) 2017-09-11
BR0311176A (pt) 2005-03-15
DK2314591T4 (da) 2021-05-10
CA2485834C (en) 2007-07-17
ES2503551T3 (es) 2014-10-07
AU2012205289A1 (en) 2012-08-09
SI2314591T1 (sl) 2014-11-28
US8518987B2 (en) 2013-08-27
EP2767539A1 (en) 2014-08-20
KR101128370B1 (ko) 2012-04-23
LT2767539T (lt) 2017-09-25
HUE034389T2 (en) 2018-02-28
EP1567529B2 (en) 2021-02-24
KR20050008715A (ko) 2005-01-21
CN1668623A (zh) 2005-09-14
AP2004003191A0 (en) 2004-12-31
EA200401503A1 (ru) 2005-06-30
US20050250845A1 (en) 2005-11-10
ES2638412T3 (es) 2017-10-20
US20140171499A1 (en) 2014-06-19
US20210179631A1 (en) 2021-06-17
EP2314591B1 (en) 2014-06-18
BRPI0311176B8 (pt) 2021-05-25
NO20045409L (no) 2004-12-10
EP1567529A2 (en) 2005-08-31
DK2314591T3 (da) 2014-09-22
KR20100119906A (ko) 2010-11-11
JP4864320B2 (ja) 2012-02-01
JP2005533068A (ja) 2005-11-04
ES2498370T5 (es) 2021-11-24
US10858369B2 (en) 2020-12-08
SI1567529T1 (sl) 2014-11-28
CY1117928T1 (el) 2017-05-17
AU2003271740A1 (en) 2003-12-31
NO331477B1 (no) 2012-01-16
US20130303790A1 (en) 2013-11-14
HK1081969A1 (en) 2006-05-26
EP2767539B1 (en) 2017-07-12
DK1567529T4 (da) 2021-05-10
SI1567529T2 (sl) 2021-08-31
EP3045460B1 (en) 2019-04-17
PT2314591E (pt) 2014-09-19
EP3045460A1 (en) 2016-07-20
ES2498370T3 (es) 2014-09-24
CY1119311T1 (el) 2018-02-14
IL165140A0 (en) 2005-12-18
EA007120B1 (ru) 2006-06-30
PL215151B1 (pl) 2013-10-31
DK1567529T3 (da) 2014-09-15
MXPA04011427A (es) 2005-02-17

Similar Documents

Publication Publication Date Title
CY1117928T1 (el) Ψευδοπολυμορφικες μορφες ενος αναστολεα πρωτεασης hiv
CY1119150T1 (el) ΜΕΘΟΔΟΙ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ (3R,3aS,6aR) ΕΞΑΫΔΡΟ-ΦΟΥΡΟ[2,3-b]ΦΟΥΡΑΝ-3-ΟΛΗΣ
DK1414828T3 (da) Antitumoranaloger
ATE497499T1 (de) Verfahren zur herstellung von hexahydrofuroä2,3- büfuran-3-ol
BR0212341A (pt) Processo para a preparação de hexaidro-furo[2,3-b]furan-3-ol
BRPI0417272B8 (pt) processo para a preparação de (3r, 3as, 6ar)-hexahidrofuro [2,3-b] furan-3-il (1s, 2r)-3-[[(4-aminofenil) sulfonil] (isobutil) amino]-1-benzil-2-hidroxipropilcarbamato
CY1106214T1 (el) Ανθελονοσιακα 1,2,4 - τριοξολανιου
ES2009839B3 (es) Rodamiento de bolas con pretensado y procedimiento y herramienta parasu fabricacion.
DK1343782T3 (da) Pyrimidinaminer som angiogenesemodulatorer
DE10294624D2 (de) Vorrichtung zur kombinierten Erfassung der Achsbeschleunigung und der Raddrehzahl sowie Druckbestimmungsverfahren
EP1652489A3 (en) Measured object mounting tool and production method of three-dimensional shape data of dental prosthesis
BR0212225A (pt) Derivados de indeno[1,2-c] isoquinolina substituìdos e processos de uso dos mesmos
AU2003287038A8 (en) Method of preparing (3r, 3as, 6ar) -3- hydroxyhexahydrofuro (2, 3-b) furan and related compounds
AR118270A2 (es) PROCESO PARA LA PREPARACIÓN DEL SOLVATO ETANOLATO DE (1S,2R)-3-[[(4-AMINOFENIL)SULFONIL](ISOBUTIL)AMINO]-1-BENCIL-2-HIDROXIPROPILCARBAMATO DE (3R,3aS,6aR)-HEXAHIDROFURO[2,3-B]FURAN-3-ILO
ES2181824T3 (es) Profarmacos de derivados de paclitaxel.
NO20062062L (no) Procsesser for preparering av forskjellige former for (S)-(+)-clopidogrel bisulfat
UY27413A1 (es) Agonistas de la oxitocina
CY1105856T1 (el) ΠΑΡΑΣΚΕΥΗ ΤΩΝ ΣΤEPΕΟΪΣΟΜEPΩΝ ΤΗΣ (3ΑΛΦΑ, 3ΑΛΦΑ/ΒΗΤΑ, 6ΑΛΦΑ/ΒΗΤΑ) ΕΞΑΫΔΡΟΦΟΥΡΟ [2,3-b] ΦΟΥΡΑΝ-3-ΟΛΗΣ
EP3313847A4 (en) PROCESS FOR THE PREPARATION OF [(S 1,2R) -3 - [[(4-AMINOPHENYL) SULFONYL] (2-METHYLPROPYL) AMINO] -2-HYDROXY-1- (PHENYLMETHYL) PROPYL] -carbamic Acid (3R, 3AS, 6AR ) HEXAHYDRO-FURO [2,3-B] FURAN-3-YL ESTER AND ITS AMORPH FORM
HUP0204380A2 (en) Device with a shaft and with at least one hub mounted on said shaft, and method for producing said device
WO2005000249A3 (en) Preparation of chemical compounds
ATE466847T1 (de) Verfahren zur herstellung von 14-beta- hydroxybaccatin-iii-1,14-carbonat
TW200514977A (en) Apparatus for inspecting leads and method thereof
FR2853659B1 (fr) Billes creuses de polyethylene
CY1115086T1 (el) Αναλογα καρβα-νουκλεοζιτων για αντιϊικη αγωγη